Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6440982 | 1.00 | ALOX5 (0.73) | ALOX5HDAC6 | |
| SCHEMBL30209466 | 1.00 | ALOX5 (0.73) | ALOX5HDAC6 | |
| SCHEMBL8892800 | 0.89 | ALOX5 (0.78) | ALOX5HDAC6 | |
| SCHEMBL9315247 | 0.88 | ALOX5 (0.80) | ALOX5HDAC6 | |
| SCHEMBL9303393 | 0.87 | ALOX5 (0.75) | ALOX5HDAC6 | |
| SCHEMBL8895036 | 0.87 | ALOX5 (0.75) | ALOX5HDAC6 | |
| SCHEMBL9301897 | 0.86 | ALOX5 (0.77) | ALOX5HDAC6 | |
| SCHEMBL8892164 | 0.86 | ALOX5 (0.75) | ALOX5HDAC6 | |
| SCHEMBL9431826 | 0.86 | ALOX5 (0.80) | ALOX5HDAC6 | |
| SCHEMBL8827857 | 0.86 | ALOX5 (0.80) | ALOX5HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0637961-A4 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE WITH LEUKOTRIENE SYNTHESIS INHIBITORS. | MILES INC (US) | 1995-08-09 | — | — | EP | claimed |
| EP-0637961-A1 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE WITH LEUKOTRIENE SYNTHESIS INHIBITORS | Bayer Corporation (US) | 1995-02-15 | — | — | EP | claimed |
| WO-1994018976-A1 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE WITH LEUKOTRIENE SYNTHESIS INHIBITORS | MILES INC. (US) | 1994-09-01 | — | — | WO | claimed |
| EP-0593976-A1 | Crystalline (R)-(-)-2-cycloheptyl-N-methylsulfonyl-4-(2-quinolinyl-methoxy)-phenyl-acetamide | BAYER AG (DE) | 1994-04-27 | — | — | EP | claimed |
| JP-6192228-A | — | — | None | — | — | JP | disclosed |
| JP-6192228-A | — | — | None | — | — | JP | disclosed |
| US-12629379-B2 | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction | NIPPON CHEMIPHAR CO., LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TAKASAKI UNIV OF HEALTH AND WELFARE (JP) | 2026-01-01 | — | — | US | disclosed |
| US-12233071-B2 | Medicament for treating cough | NIPPON CHEMIPHAR CO., LTD. (JP) | 2025-02-25 | — | — | US | disclosed |
| EP-4501357-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS | Takasaki University of Health and Welfare (JP) | 2025-02-05 | — | — | EP | disclosed |
| CN-119233829-A | Pharmaceutical composition for preventing, inhibiting or treating symptoms associated with pseudoallergy | 学校法人高崎健康福祉大学 | 2024-12-31 | — | — | CN | disclosed |
| WO-2023190826-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS | 学校法人 高崎健康福祉大学 | 2023-10-05 | — | — | WO | disclosed |
| US-5391555-A | Administering 2-(4(2-quinolinyl-methoxy)-phenyl)-acetic acid derivatives; Crohn's disease | MILES INC. (US) | 1995-02-21 | — | — | US | disclosed |
| EP-0637961-A1 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE WITH LEUKOTRIENE SYNTHESIS INHIBITORS | Bayer Corporation (US) | 1995-02-15 | — | — | EP | disclosed |
| WO-1994018976-A1 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE WITH LEUKOTRIENE SYNTHESIS INHIBITORS | MILES INC. (US) | 1994-09-01 | — | — | WO | disclosed |
| JP-H06192228-A | CRYSTALLINE (R)-(-)-2-XYCLOHEPTYL-N-METHYLSULFONYL-(4-(2-QUINOLINYLMETHOXY)-PHENYL)-ACETOAMIDE | BAYER AG | 1994-07-12 | — | — | JP | disclosed |
| JP-H06192228-A | CRYSTALLINE (R)-(-)-2-XYCLOHEPTYL-N-METHYLSULFONYL-(4-(2-QUINOLINYLMETHOXY)-PHENYL)-ACETOAMIDE | BAYER AG | 1994-07-12 | — | — | JP | disclosed |
| EP-0593976-A1 | Crystalline (R)-(-)-2-cycloheptyl-N-methylsulfonyl-4-(2-quinolinyl-methoxy)-phenyl-acetamide | BAYER AG (DE) | 1994-04-27 | — | — | EP | disclosed |
| EP-0593976-A1 | Crystalline (R)-(-)-2-cycloheptyl-N-methylsulfonyl-4-(2-quinolinyl-methoxy)-phenyl-acetamide | BAYER AG (DE) | 1994-04-27 | — | — | EP | disclosed |
| EP-0593976-A1 | Crystalline (R)-(-)-2-cycloheptyl-N-methylsulfonyl-4-(2-quinolinyl-methoxy)-phenyl-acetamide | BAYER AG (DE) | 1994-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12233071-B2 | Medicament for treating cough | P2RX4, P2RX3, P2RX5 | ALOX5 1345/4885HDAC6 897/4885 |
| US-12629379-B2 | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction | HRH2, HRH4, HRH1 | ALOX5 600/4885HDAC6 963/4885 |
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TRPV1, TRPV4, TRPV5 | ALOX5 696/4885HDAC6 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.